• 한국식품과학회지
• /
• 제46권2호
• /
• pp.180-188
• /
• 2014

본 실험에서는 coenzyme $Q_{10}$을 cyclodextrin, starch를 이용하여 각각 복합체를 형성하고 형성된 복합체의 용해도 및 구조적 특성을 확인하였다. Starch 복합체는 용해 온도가 증가할수록 복합체 및 복합체내의 coenzyme $Q_{10}$의 용해도가 유의적으로 증가하는데 비해 cyclodextrin 복합체는 $37^{\circ}C$에서 coenzyme $Q_{10}$의 최대 용해도를 보였으며 이후 $50^{\circ}C$에서는 강하게 aggreagation이 일어났고, $80^{\circ}C$에서는 약해진 결합에 의해 복합체가 깨짐으로써 coenzyme $Q_{10}$이 물 위에 뜨는 형상을 나타내었다. 두 복합체의 구조적 차이를 FT-IR, XRD, DSC를 통하여 확인한 결과 cyclodextrin 복합체는 coenzyme $Q_{10}$의 isoprenoid chain에 주로 포접이 되어 있는데 반해 starch 복합체는 coenzyme $Q_{10}$의 isoprenoid chain 뿐만 아니라 benzoquinone ring에도 포접되어 있는 것을 확인하였고, 또한 starch 복합체가 cyclodextrin 복합체에 비해 coenzyme $Q_{10}$ 무정형영역이 더 크게 증가되어 있는 것을 확인하였다. In vitro simulated digestion model을 통하여 각 소화기관 별 복합체의 방출 패턴을 확인 한 결과 두 복합체 모두 구강, 위장의 효소 및 조건에 비해 소장의 효소와 조건에서 유의적으로 크게 coenzyme $Q_{10}$의 방출이 확인되었다. 따라서 coenzyme $Q_{10}$은 cyclodextrin, starch와 포접되어 복합체를 형성함으로서 생체이용율의 향상을 기대할 수 있다.

• 미생물학회지
• /
• 제46권1호
• /
• pp.46-51
• /
• 2010

Coenzyme Q10 (CoQ10)은 전자전달계에 필수적인 요소로 질병치료 및 완화에 도움이 되어 산업 의학적으로 그 활용도가 넓어지고 있다. 본 연구에서는 새로운 CoQ10 생산균주를 선별하기 위하여 quinone 분석 결과 CoQ10을 함유하는 것으로 확인된 8종 미생물의 생장특성과 CoQ10 생산능을 1차 조사하여, 세균류인 Paracoccus denitrificans KCTC 2530과 Asaia siamensis KCTC 12914를 대량배양을 통한 CoQ10 생산에 유리한 특성을 갖는 균주로 선별하였다. 이들 세균류의 생장 및 CoQ10 생산의 최적조건을 플라스크배양으로 조사한 결과, M81 배지를 기반으로 하여 탄소원으로는 4% fructose, 질소원으로는 2% yeast extract가 가장 좋은 것으로 조사되었으며, 배양온도는 $30^{\circ}C$, 배지의 최적 pH는 P. denitrificans KCTC 2530의 경우 pH 6.0, A. siamensis KCTC 12914의 경우 pH 8.0으로 조사되었다. 이를 바탕으로 2 L fed-batch culture를 수행한 결과, P. denitrificans KCTC 2530은 1 L 당 $14.34{\pm}0.473$ mg, A. siamensis KCTC 12914는 $12.53{\pm}0.231$ mg의 CoQ10을 생산하였다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제13권4호
• /
• pp.321-326
• /
• 2009

The antioxidant effect of $CoQ_{10}$ on N-nitrosodiethylamine (NDEA)-induced oxidative stress was investigated in mice. Food intake and body weight were similar in both $CoQ_{10}$ and control groups during the 3-week experimental period. NDEA significantly increased the activities of typical marker enzymes of liver function (AST, ALT and ALP) both in control and $CoQ_{10}$ groups. However, the increase of plasma aminotransferase activity was significantly reduced in the $CoQ_{10}$ group. Lipid peroxidation in various tissues, such as heart, lung, liver, kidney, spleen and plasma, was significantly increased by NDEA, but this increase was significantly reduced by 100 mg/kg of $CoQ_{10}$. Superoxide dismutase activity increased significantly upon NDEA-induced oxidative stress in both the control and $CoQ_{10}$ groups with the effect being less in the $CoQ_{10}$ group. Catalase activity decreased significantly in both the control and $CoQ_{10}$ groups treated with NDEA, again with the effect being less in the $CoQ_{10}$ group. The lesser effect on superoxide dismutase and catalase in the NDEA-treated $CoQ_{10}$ group is indicative of the protective effect $CoQ_{10}$. Thus, $CoQ_{10}$ can offer useful protection against NDEA-induced oxidative stress.

• Biomolecules & Therapeutics
• /
• 제24권2호
• /
• pp.171-177
• /
• 2016

Statins, HMG-CoA reductase inhibitors, are known to cause serious muscle injuries (e.g. myopathy, myositis and rhabdomyolysis), and these adverse effects can be rescued by co-administration of coenzyme $Q_{10}$ ($CoQ_{10}$) with statins. The goal of the current research is to assess the efficacy of combined treatment of $CoQ_{10}$ with Atorvastatin for hyperlipidemia induced by high-fat diet in SD rats. 4-week-old Sprague-Dawley male rats were fed normal diet or high-fat diet for 6 weeks. Then, rats were treated with either Statin or Statin with various dosages of $CoQ_{10}$ (30, 90 or 270 mg/kg/day, p.o.) for another 6 weeks. Compared to Statin only treatment, $CoQ_{10}$ supplementation significantly reduced creatine kinase and aspartate aminotransferase levels in serum which are markers for myopathy. Moreover, $CoQ_{10}$ supplementation with Statin further reduced total fat, triglycerides, total cholesterol, and low-density lipoprotein-cholesterol. In contrast, the levels of high-density lipoprotein-cholesterol and $CoQ_{10}$ were increased in the $CoQ_{10}$ co-treated group. These results indicate that $CoQ_{10}$ treatment not only reduces the side effects of Statin, but also has an anti-obesity effect. Therefore an intake of supplementary $CoQ_{10}$ is helpful for solving problem of obese metabolism, so the multiple prescription of $CoQ_{10}$ makes us think a possibility that can be solved in being contiguous to the obesity problem, a sort of disease of the obese metabolism.

• Fisheries and Aquatic Sciences
• /
• 제11권4호
• /
• pp.219-223
• /
• 2008

To increase the level of $CoQ_{10}$ production in mass culture, the effects of pH and light irradiation on $CoQ_{10}$ production by Rhodobacter sphaeroides were investigated in a 1-L bioreactor. $CoQ_{10}$ production was growth-associated, and the highest production of $CoQ_{10}$ (1.69 mg/g dry cell) was obtained under uncontrolled pH: this production was 1.7 times higher than that obtained at controlled pH 7. Therefore, pH was a key factor affecting $CoQ_{10}$ production. The effect of light irradiation on $CoQ_{10}$ production was negligible. This result offers an advantage for mass production of $CoQ_{10}$.

• Journal of Microbiology and Biotechnology
• /
• 제22권2호
• /
• pp.230-233
• /
• 2012

Rhizobium radiobacter T6102 was morphologically purified by the aniline blue agar plates to give two distinct colonies; white smooth mucoid colony (T6102W) and blue rough colony (T6102B). The coenzyme $Q_{10}$ ($CoQ_{10}$) was produced just by T6102W, showing 2.0 mg/g of $CoQ_{10}$ content, whereas the T6102B did not produce the $CoQ_{10}$. All of the used $CoQ_{10}$ biosynthetic precursors enhanced the $CoQ_{10}$ production by T6102W. Specifically, the supplementation of 0.75 mM isopentenyl alcohol improved the $CoQ_{10}$ concentration (19.9 mg/l) and content (2.4 mg/g) by 42% and 40%, respectively.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 2006년도 Proceedings of The Convention
• /
• pp.127-130
• /
• 2006

Coenzyme Q10(CoQ10) is a biological quinine compound that is widely found in living organisms including yeast, plants, and animals. CoQ10 has two major physiological activities:(a)mitochondrial electron-transport activity and (b )antioxidant activity. Various clinical applications are also available: Parkinson's disease, Heart disease, diabetes. Because of its various application filed, the market size of CoQ10 is continuously expanding all over the world. A Japanese company, Nisshin Pharma Inc. is the first industrial producer of CoQ10(1974). CoQ10 can be produced by fermentation and chemical synthesis. In several companies, these two methods are used for the production of CoQ10:chemical synthesis - Yungjin, Daewoong, Nishin Parma; fermentation - Kaneka, Kyowa, Yungjin, etc. Researchs in microbial production of CoQ10 have several steps: screening of producing microorganisms, strain development, fermentation process, purification process, scale-up process, plant production. Several strategies are available for the strain development : Random mutation and screening, directed metabolic engineering. For the optimization of fermentation process, various conditions (nutrient, aeration, temperature, culture type, etc.) are considered. Purification is one of the most important step because the quality of final products entirely depends on its purity. The production cost will be reduced and the quality of the CoQ10 will be impoved by continuous researches in strain development, fermentation process, purification process.

• 한국약용작물학회:학술대회논문집
• /
• 한국약용작물학회 2006년도 Proceedings of The Convention of The Korean Society of Applied Pharmacology
• /
• pp.127-130
• /
• 2006

Coenzyme Q10(CoQ10) is a biological quinine compound that is widely found in living organisms including yeast, plants, and animals. CoQ10 has two major physiological activities:(a)mitochondrial electron-transport activity and (b)antioxidant activity. Various clinical applications are also available : Parkinson's disease, Heart disease, diabetes. Because of its various application filed, the market size of CoQ 10 is continuously expanding all over the world. A Japanese company, Nisshin Pharma Inc. is the first industrial producer of CoQ10(1974). CoQ10 can be produced by fermentation and chemical synthesis. In several companies, these two methods are used for the production of CoQ10:chemical synthesis - Yungjin, Daewoong, Nishin Parma; fermentation - Kaneka, Kyowa, Yungjin, etc. Researchs in microbial production of CoQ10 have several steps: screening of producing microorganisms, strain development, fermentation process, purification process, scale-up process, plant production. Several strategies are available for the strain development : Random mutation and screening, directed metabolic engineering. For the optimization of fermentation process, various conditions (nutrient, aeration, temperature, culture type, etc.) are considered. Purification is one of the most important step because the quality of final products entirely depends on its purity. The production cost will be reduced and the quality of the CoQ10 will be impoved by continuous researches in strain development, fermentation process, purification process.

• 한국가금학회지
• /
• 제43권1호
• /
• pp.47-54
• /
• 2016

Coenzyme Q10(CoQ10)은 자연계에 널리 분포하는 화합물로 세포호흡과 항산화제로서 그 기능이 잘 알려졌지만, 최근 유전자들의 발현 조절자로서의 가능성도 제시되었다. 따라서 본 연구는 산란계에서 CoQ10의 첨가 급이가 콜레스테롤과 지방산 대사관련 유전자들의 발현에 미치는 영향을 관찰하고자 실시하였다. Lohmann Brown(40주령) 36수를 CoQ10의 첨가원에 따라 대조군(CON, basal diet(BD)), CoQ10 건조분말 급여군(T1, BD+CoQ10 100 mg/kg 사료) 및 CoQ10 건조분말 유화처리군(T2, BD+micellar of CoQ10 100 mg/kg 사료) 등 모두 3처리구로 설정하여 5주간 사양시험을 실시하였다. 시험 종료 후 각 개체의 간으로부터 total RNA를 추출하고, real-time PCR을 이용하여 유전자들의 발현을 분석하였다. 콜레스테롤 합성 과정에서 주요 조절 효소인 HMGCoA reductase(HMGCR)의 유전자 발현은 대조구에 비하여 CoQ10 분말첨가인 T1과 유화처리된 T2 처리구에서 모두 약 50%씩 억제되었다(p<0.05). 내생 콜레스테롤의 합성을 촉진시키는 전사인자인 SREBP2 mRNA 발현 또한 대조구와 비교해서 T1과 T2에서 각각 30%와 40% 감소하였다(p<0.05). CoQ10의 첨가 급이는 대조구에 비하여 liver X receptor(LXR) 유전자가 약 30~35% 그 발현이 억제되었으며, sterol regulatory element-binding proteins(SREBPs)1 또한 T2에서 약 40% 유전자 발현이 감소하였다(P<0.05). 전사인자인 $PPAR{\gamma}$와 XBP1은 CoQ10에 의하여 약 15~40% 수준으로 효과적으로 억제됨을 확인하였다(p<0.05). 세포 내부로의 에너지 공급원인 포도당의 흡수를 담당하는 GLUT2는 약 35~60% 그리고 GLUT8은 약 25~30%의 유전자발현 각각 감소함을 보였다(p<0.05). CoQ10의 섭취는 중성지방 합성을 위한 지방합성효소(FASN)의 유전자 발현을 분말처리군에서 약 30%, 유화처리군에서 약 65% 억제됨을 확인하였다(P<0.05). 본 연구결과는 CoQ10 첨가급여가 콜레스테롤 및 지방대사 관련 유전자 발현에 영향을 미치며, 세포내 콜레스테롤과 지방의 생성도 억제할 수 있음을 보여주었다.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 2006년도 Proceedings of The Convention
• /
• pp.139-145
• /
• 2006

Kaneka Corporation (Kaneka) has been manufacturing CoQ10 under GMP regulation since 1977. Kaneka has a sophisticated quality control system and has been supplying high quality CoQ10 materials to the worldwide customers (Kaneka CoQ10) for about 30 years. Kaneka CoQ10 is characterized by a lot of safety data, which are derived from clinical trials with healthy volunteers (single-dose and 4-week multi-dose safety studies), animal studies (13-week sub-chronic study in dogs and 52-week chronic study in rats), three types of mutagenicity test, six type of skin irritation test (for cosmetics), and others. The risk assessment of CoQ10 was performed by Council for Responsible Nutrition (USA). They reviewed many of available clinical data including clinical trials using Kaneka Q10, and concluded that the upper level for supplements (ULS) of CoQ10 is 1,200 mg/day (Hathcock and Shao. 2006, Regulatory Toxicology and Pharmacology, 45, 282 - 288).